Tracking Susceptibility and Reducing Resistance - Fluoroquinolones at the Forefront in the Fight Against Bacterial Pathogens
Question 14
Could you comment on the activity of levofloxacin, macrolide or beta-lactam resistant S. pneumoniae?
As shown by our Spanish study results and supported by the PROTEKT US surveillance study it is clear that there is no associated increase in fluoroquinolone resistance demonstrated by beta-lactam or macrolide resistant S. pneumoniae. The latest US report notes that more than 98% of erythromycin resistant S. pneumoniae isolates remain susceptible to levofloxacin, and, in addition, the genotypic mechanisms responsible for the resistance had little impact on susceptibility to levofloxacin (Table 4).
Table 4. Antimicrobial susceptibility of erythromycin-resistant isolates, by genotype, year 6 (2005-2006) of the PROTEKT US surveillance study
Susceptibility to Levofloxacin (%) |
|||
| Genotype | Susceptible | Intermediate | Resistant |
| erm (B)a | 98.2 | 0.2 | 1.6 |
| mef (A)b | 98.9 | 0.1 | 1.0 |
| erm (B) + mef (A)c | 98.8 | 0.2 | 1.0 |
an = 448
bn = 1,282
cn = 575
| Abbreviations: | PROTEKT US = Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States. |
Adapted from reference (11).
 |
 |
 |
LATEST TOPICS
RELATED ARTICLES
